Skip to main content
Premium Trial:

Request an Annual Quote

Getting into the Game

As our sister publications Pharmacogenomics Reporter and In Sequence report, Illumina has gotten into the personal genome-sequencing game. For $48,000 Illumina will sequence someone's genome, using its Genome Analyzer II, and provided that person has a prescription. Illumina will do the raw data analysis but for the user to get all the risk information, the consumer will go to Illumina's partners, 23andMe, Navigenics, Decode, and Knome.

At Genomeboy, Misha Angrist adds that four people are currently using the service including Illumina CEO Jay Flatley. Daniel MacArthur also has a run-down of the new service. He writes that he has "every expectation that Illumina will become a serious player" in the field. Thomas Mailund adds that what dampens his excitement is the price. "While Illumina's offer is half the price of Knome, it is still far from DeCodeMe (1M markers for $1000) or 23AndMe (500K markers for $400) and not really in the range of the average citizens," he writes.

On a related note, Francis Collins has used 23andMe, Navigenics, and DecodeMe's services, according to Angrist. Collins noticed differences in the companies' interpretations, likely due to the different sets of SNPs tested.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.